Adjuvant durvalumab for esophageal squamous cell carcinoma after neoadjuvant chemoradiotherapy: a placebo-controlled, randomized, double-blind, phase II study
Sign Up to like & getrecommendations! Published in 2022 at "ESMO Open"
DOI: 10.1016/j.esmoop.2022.100385
Abstract: Background We evaluated the efficacy of adjuvant durvalumab after neoadjuvant concurrent chemoradiotherapy (CCRT) in patients with esophageal squamous cell carcinoma (ESCC). Patients and methods This randomized, double-blind, phase II study included patients with ESCC who… read more here.
Keywords: durvalumab; cell carcinoma; adjuvant durvalumab; ccrt ... See more keywords